Ignite Creation Date:
2024-05-05 @ 4:39 PM
Last Modification Date:
2024-10-26 @ 9:22 AM
Study NCT ID:
NCT00286780
Status:
COMPLETED
Last Update Posted:
2010-08-13
First Post:
2006-02-03
Brief Title:
Phase 2 Safety and Efficacy Study of AT-101 in Combination With Rituximab in Patients With Chronic Lymphocytic Leukemia
Sponsor:
Ascenta Therapeutics
Organization:
Ascenta Therapeutics
Organization Data
Organization:
Ascenta Therapeutics
Class:
INDUSTRY
Study ID:
AT-101-CS-008
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Ascenta Therapeutics
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
None
Responsible Party Affiliation:
None
Old Name:
Brian Wood Associate Director Clinical Development
Old Organization:
Ascenta Therapeutics